General Biotechnology

Pharma’s quiet superpower isn’t just R&D—it’s timing.
In the race to extend exclusivity, the winners aren’t always the ones with the most molecules. They’re the ones with the most precise calendars.
A new post from DrugPatentWatch lays out how phar…

Pharma doesn’t “miss” patent windows. It tracks them.
The real question is how.
In a world where patent terms, regulatory exclusivities, and jurisdiction-specific rules can make or break a product’s commercial runway, the companies that win global exte…

Generic drugs are no longer “copy and paste.” They’re a precision engineering problem.
For years, the generics playbook was simple: file the paperwork, prove sameness, and move on. But the market has evolved—and so has the bar for approval. In today’…

The Patent Clock Is Ticking—And the Best Talent Is Already in the Room
In pharma, the most valuable people don’t always announce themselves. They don’t need to. They’re already doing the work—drafting, prosecuting, negotiating, and stress-testing claim…

Pharma patent litigation is often described as a line item: legal fees, expert reports, court filings. But that’s the part you can see.
The real cost is the stuff that doesn’t show up neatly on an invoice—until it quietly changes the economics of a lau…

Pharma’s “reformulation playbook” is getting a new lease on life—and 505(b)(2) is the engine.
For years, the industry narrative has been simple: reformulation is innovation. But if you look closely at how the 505(b)(2) pathway is being used, a differen…

Drug spend is one of the few line items in healthcare that still behaves like a black box—until you turn it into a calendar.
That’s the core promise behind the procurement playbook in the DrugPatentWatch piece, “Patent Expiration Data: The Procurement …

The “Drug Patent Cliff” Isn’t Just a Pharma Story—It’s a Procurement Risk You Can Model
If you manage sourcing, contracting, or formulary strategy, you already know the uncomfortable truth: the biggest cost shocks in healthcare rarely arrive with a pre…

The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Can Imperil Sponsor Patents
Clinical trials are supposed to be about evidence—data, safety, efficacy. But increasingly, the real risk isn’t only in the protocol. It’s in the software…

The “Hard 20” in New Zealand Isn’t Just a Legal Detail—It’s a Business Strategy
In drug development, timing is everything. But in New Zealand, timing is also structural.
A recent DrugPatentWatch deep dive on drug patents in New Zealand highlights a rea…